Europe Inhalation Therapy Nebulizer Market Overview
The Europe inhalation therapy nebulizer market size was valued at USD 398.28 million in 2022 and is expected to reach USD 623.25 million by 2030, exhibiting a CAGR of 5.9% during the forecast period (2023-2030).
A nebulizer is a compact device that creates a mist of liquid medication that is simple to breathe in. Through a facemask or attached mouthpiece, people sit next to the machine & breathe in the medication. This enables the medication to go straight to the lungs. Various lung conditions can be treated using nebulizers such as asthma. It offers many advantages such as a rapid onset of action, proven efficacy, an outstanding safety profile, and extensive use in treating various respiratory ailments. Nebulization therapy benefits most patients, including children, the elderly, those using mechanical breathing machines, those with cognitive impairments, and those who cannot utilize other inhalation equipment.
Source: DataM Intelligence Analysis (2022)
Europe Inhalation Therapy Nebulizer Market Dynamics and Trends
The major factors driving the Europe inhalation therapy nebulizer market growth are the increasing elderly population, rising incidence of chronic respiratory diseases, and increasing demand for home healthcare device.
The increasing geriatric population is expected to drive market growth.
The growing geriatric populations and associated conditions such as cough issues, deteriorating respiratory conditions, community-acquired pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and non-pneumonic respiratory tract infections, frequently create market opportunities and are expected to drive market growth.
In the world, the most of the elderly population resides in Europe, according to Statista data from 2021. Europe leads with 19% of the population over 65 years old. Germany has the highest elderly population at 17.78 million, followed by Italy with 13.76 million, France with 13.16 million, and the U.K. with 12.24 million.
The UN estimates that between 1950 and 2010, life expectancy rose from 46 to 68 years and it will reach 73.2 years in 2020. Statista states that 10% of the world's population was 65 years or older and 26% were 15 or younger in 2021.
Moreover, the European Union and other countries worldwide are expected to deal with increasingly aging populations this century, according to World Economic Forum 2022. By 2100, it is anticipated that more than 30% of EU citizens will be 65 or older. This population change may significantly impact the region's economic prospects. These factors are expected to result in increasing demand for inhalation therapy nebulizers, thereby driving the market growth.
Side effects associated with drug inhalation are likely to hinder the market growth.
Complications and side effects associated with drug inhalation, unavailability of a single effective inhaler device, and lack of awareness are restraining the market growth. The most common side effects of nebulizer treatment are rapid heartbeat, jitteriness, and anxiety. Less frequent side effects may include headache, nausea, vomiting, or throat irritation.
COVID-19 Impact on Europe Inhalation Therapy Nebulizer Market
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. According to a January 2022 paper titled "Impact of COVID-19 on adults with asthma: a mixed methods analysis from a UK-wide survey," patients with COVID-19 had worse asthma management and used inhalers more frequently.
Moreover, the article titled "Guidance on nebulization during the current COVID-19 pandemic," which was published in PubMed Central in January 2021, noted that patients were wary of using immunosuppressive medications and inhalation drugs that were thought to be potential sources of viral transmission because they were aware that SARS-CoV-2 could spread through the air. Nevertheless, those with COPD or asthma had to continue taking all inhaled medications as prescribed. Thus, COVID-19 had a significant effect on the nebulizer market.
Europe Inhalation Therapy Nebulizer Market Segment Analysis
The hospital segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The hospital segment is the highest market holder in the Europe inhalation therapy nebulizer market. The Europe inhalation therapy nebulizer market is segmented based on distribution channel as hospitals, ambulatory surgical centers and others. The hospital segment is the largest market shareholder due to the increasing adoption of these nebulizers for therapy by various hospitals globally, increasing technological advancements, rising asthma cases and novel product launches.
According to the National Institute for Health and Care Excellence (NICE), 185 people in the UK are admitted to hospitals with an asthma attack every day and 5.4 million people are using drugs for asthma.
In contrast to the 6.5% of general practitioner patients in England (one in fifteen) who were anticipated to have the illness in 2019–20, there were 41,150 hospital admissions with asthma as the primary diagnosis in 2020–21, with an average age of 41. Asthma can occasionally be fatal; in 2020, asthma was listed as the leading cause of 1,335 fatalities in England and Wales. 61% of people in this group are 80 or older.
There is no known cure for asthma, but nebulizer manages to control the symptoms. Patients are frequently utilizing inhalers, though the medications prescribed which depend on various factors, including the kind and intensity of symptoms. These factors drive the hospital segment growth.
Source: DataM Intelligence Analysis (2022)
Europe Inhalation Therapy Nebulizer Market Geographical Analysis
France holds the largest market share in the Europe inhalation therapy nebulizer market.
France holds a dominant position in the Europe inhalation therapy nebulizer market due to its large population, excellent medical infrastructure, and high-income levels. One of the key clinical tasks of pulmonologists in the private practice setting in France is the management of chronic obstructive pulmonary disease (COPD). Following French recommendations, multidisciplinary teams should manage COPD patients, who generally have numerous comorbidities. Respiratory-connected devices were emphasized as a vital new strategy for improving patient care during a COPD exacerbation.
According to GlaxoSmithKline Survey 2021, 2.6 million people in France are currently anticipated to have a chronic obstructive pulmonary disease (COPD), and by 2025, the number is expected to rise to 2.8 million. Data on COPD management in the context of private healthcare are currently lacking.
The population of people with COPD at any given time is made up of three different groups: those who had the disease last year and were still alive during that year, those who had it incidentally in the population of people over 44 the year before, and those who had it frequently in the population of people over 44 the year before. The COPD population was divided into groups based on gender, whether or not they smoked, and the degree of airway restriction.
Source: DataM Intelligence Analysis (2022)
Europe Inhalation Therapy Nebulizer Companies and Competitive Landscape
The inhalation therapy nebulizer market is moderately competitive with the presence of local and Europe companies such as Rossmax International Ltd., Boehringer Ingelheim GmbH, OMRON Corporation, Koninklijke Philips N.V., PARI Pharma, BD, Medline Industries, Inc., Briggs Healthcare, GF Health Products, Inc., Vectura Group plc, and Beurer GmBH.
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, on October 28, 2020, the European Commission (EC) approved the use of ARIKAYCE Liposomal 590 mg Nebulizer Dispersion ("ARIKAYCE") for the treatment of adults without cystic fibrosis who have nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC).
Omron Corporation
Overview: Omron's primary business is the manufacture and sale of automation components, equipment, and systems, but it is generally known for medical equipment such as digital thermometers, blood pressure monitors, and nebulizers. Omron was established by Kazuma Tateishi in 1933 (as the Tateisi Electric Manufacturing Company) and incorporated in 1948.
Product Portfolio: The MicroAir U100 Nebulizer is a small, handheld battery-operated nebulizer. It uses unique, vibrating mesh technology with fast misting to help deliver the optimal amount of medication.
The Europe inhalation therapy nebulizer market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.
